Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516813 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02516813 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 52 participants.
The verdict
NCT02516813, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
M3814 was an investigational drug that is being evaluated for the treatment of participants with locally advanced tumors. The main purposes of this study was to determine the safety, the tolerability and the efficacy of M3814 in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).
Interventions
- DRUG M3814 100 mg
- DRUG M3814 200 mg
- DRUG M3814 300 mg
- DRUG M3814 400 mg
- DRUG M3814 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516813
The ClinicalTrials.gov registry entry for NCT02516813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which M3814 100 mg is the first listed.
NCT02516813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516813 about?
NCT02516813 is a clinical study titled "Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy". M3814 was an investigational drug that is being evaluated for the treatment of participants with locally advanced tumors. The main purposes of this study was to determine the safety, the tolerability and the efficacy of M3814 in combination with radiotherapy and in combination with chemoradiotherapy...
What is the current status of trial NCT02516813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2015-09-15. Estimated completion is 2021-11-19.
What interventions are being tested in trial NCT02516813?
The interventions under investigation include: M3814 100 mg (DRUG), M3814 200 mg (DRUG), M3814 300 mg (DRUG), M3814 400 mg (DRUG), M3814 50 mg (DRUG).
Who is sponsoring clinical trial NCT02516813?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.